EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as gefitinib and erlotinib, have shown remarkable activity in the patients with NSCLC, and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon (in-frame deletions) and exon 21 (L858R point mutation), which are found to be more prevalent in Asian patients [4,5].